From this systematic review and meta-analysis, use of erythropoietin-stimulating agents (ESAs) to achieve high hemoglobin targets in patients with chronic kidney disease (CKD) did not significantly improve health-related quality of life (HRQOL) compared to using ESAs to achieve lower hemoglobin targets.

http://www.2minutemedicine.com/erythropoietin-stimulating-agents-may-not-improve-quality-of-life-for-patients-with-chronic-kidney-disease/